Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.31
SPPI's Cash to Debt is ranked lower than
76% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. SPPI: 1.31 )
Ranked among companies with meaningful Cash to Debt only.
SPPI' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 10.00 Max: 17918
Current: 1.31
0.2
17918
Equity to Asset 0.52
SPPI's Equity to Asset is ranked lower than
68% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SPPI: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
SPPI' s Equity to Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.59 Max: 0.95
Current: 0.52
0.2
0.95
F-Score: 4
Z-Score: 0.68
M-Score: -3.59
WACC vs ROIC
8.67%
-13.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -15.11
SPPI's Operating margin (%) is ranked higher than
63% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. SPPI: -15.11 )
Ranked among companies with meaningful Operating margin (%) only.
SPPI' s Operating margin (%) Range Over the Past 10 Years
Min: -484.81  Med: -45.90 Max: 29.82
Current: -15.11
-484.81
29.82
Net-margin (%) -20.59
SPPI's Net-margin (%) is ranked higher than
62% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. SPPI: -20.59 )
Ranked among companies with meaningful Net-margin (%) only.
SPPI' s Net-margin (%) Range Over the Past 10 Years
Min: -443.64  Med: -44.98 Max: 35.32
Current: -20.59
-443.64
35.32
ROE (%) -15.70
SPPI's ROE (%) is ranked higher than
64% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. SPPI: -15.70 )
Ranked among companies with meaningful ROE (%) only.
SPPI' s ROE (%) Range Over the Past 10 Years
Min: -72  Med: -23.84 Max: 39.33
Current: -15.7
-72
39.33
ROA (%) -7.88
SPPI's ROA (%) is ranked higher than
69% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. SPPI: -7.88 )
Ranked among companies with meaningful ROA (%) only.
SPPI' s ROA (%) Range Over the Past 10 Years
Min: -61.52  Med: -12.49 Max: 24.07
Current: -7.88
-61.52
24.07
ROC (Joel Greenblatt) (%) -2354.13
SPPI's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SPPI: -2354.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPPI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5547.35  Med: -1989.97 Max: 3053.13
Current: -2354.13
-5547.35
3053.13
Revenue Growth (3Y)(%) -15.40
SPPI's Revenue Growth (3Y)(%) is ranked lower than
69% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SPPI: -15.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPPI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -4.60 Max: 202.1
Current: -15.4
0
202.1
» SPPI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SPPI Guru Trades in Q2 2015

Jim Simons 1,785,917 sh (+28.37%)
Paul Tudor Jones Sold Out
» More
Q3 2015

SPPI Guru Trades in Q3 2015

Paul Tudor Jones 30,458 sh (New)
Jim Simons 1,773,517 sh (-0.69%)
» More
Q4 2015

SPPI Guru Trades in Q4 2015

Jim Simons 2,591,319 sh (+46.11%)
Paul Tudor Jones 39,787 sh (+30.63%)
» More
Q1 2016

SPPI Guru Trades in Q1 2016

Jim Simons 3,304,100 sh (+27.51%)
Paul Tudor Jones 11,976 sh (-69.90%)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:XNPT, NAS:OTIC, NAS:TLGT, NAS:CLDX, NAS:AMRN, NAS:MNKD, NAS:OMER, NAS:ACRS, OTCPK:PTCHF, NAS:GERN, NAS:MYOK, NAS:PGNX, NAS:VNDA, NAS:ENTA, NAS:AGEN, NAS:WVE, NAS:AIMT, NAS:ARNA, NAS:LOXO, NAS:SGMO » details
Traded in other countries:NTR.Germany,
Spectrum Pharmaceuticals Inc is a biotechnology company with fully integrated commercial and drug development operations with a primary focus on oncology and hematology.

Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.

Ratios

vs
industry
vs
history
P/B 2.16
SPPI's P/B is ranked higher than
68% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. SPPI: 2.16 )
Ranked among companies with meaningful P/B only.
SPPI' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.05 Max: 5.24
Current: 2.16
0.64
5.24
P/S 2.54
SPPI's P/S is ranked higher than
84% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. SPPI: 2.54 )
Ranked among companies with meaningful P/S only.
SPPI' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 3.61 Max: 467.69
Current: 2.54
1.06
467.69
PFCF 30.23
SPPI's PFCF is ranked lower than
56% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. SPPI: 30.23 )
Ranked among companies with meaningful PFCF only.
SPPI' s PFCF Range Over the Past 10 Years
Min: 6.65  Med: 17.79 Max: 76.12
Current: 30.23
6.65
76.12
POCF 84.81
SPPI's POCF is ranked lower than
85% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. SPPI: 84.81 )
Ranked among companies with meaningful POCF only.
SPPI' s POCF Range Over the Past 10 Years
Min: 6.62  Med: 13.85 Max: 98.7
Current: 84.81
6.62
98.7
EV-to-EBITDA 76.37
SPPI's EV-to-EBITDA is ranked lower than
86% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. SPPI: 76.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
SPPI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1739.5  Med: -1.60 Max: 84.8
Current: 76.37
-1739.5
84.8
Current Ratio 2.90
SPPI's Current Ratio is ranked lower than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SPPI: 2.90 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.75 Max: 16.82
Current: 2.9
0.56
16.82
Quick Ratio 2.84
SPPI's Quick Ratio is ranked lower than
63% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. SPPI: 2.84 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.61 Max: 16.8
Current: 2.84
0.56
16.8
Days Inventory 85.66
SPPI's Days Inventory is ranked higher than
64% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. SPPI: 85.66 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s Days Inventory Range Over the Past 10 Years
Min: 78.11  Med: 109.12 Max: 281.63
Current: 85.66
78.11
281.63
Days Sales Outstanding 41.87
SPPI's Days Sales Outstanding is ranked higher than
68% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. SPPI: 41.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.09  Med: 100.74 Max: 138.24
Current: 41.87
9.09
138.24
Days Payable 354.12
SPPI's Days Payable is ranked higher than
89% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. SPPI: 354.12 )
Ranked among companies with meaningful Days Payable only.
SPPI' s Days Payable Range Over the Past 10 Years
Min: 89.64  Med: 286.45 Max: 7902.06
Current: 354.12
89.64
7902.06

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 83.72
SPPI's Price/Tangible Book is ranked lower than
99% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SPPI: 83.72 )
Ranked among companies with meaningful Price/Tangible Book only.
SPPI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.66  Med: 5.97 Max: 6030
Current: 83.72
0.66
6030
Price/Projected FCF 1.14
SPPI's Price/Projected FCF is ranked higher than
84% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 3.44 vs. SPPI: 1.14 )
Ranked among companies with meaningful Price/Projected FCF only.
SPPI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.42 Max: 7.58
Current: 1.14
0.94
7.58
Price/Median PS Value 0.71
SPPI's Price/Median PS Value is ranked higher than
69% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SPPI: 0.71 )
Ranked among companies with meaningful Price/Median PS Value only.
SPPI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 2.27 Max: 15937.5
Current: 0.71
0.16
15937.5
Earnings Yield (Greenblatt) (%) -6.00
SPPI's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. SPPI: -6.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPPI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 11.60 Max: 2183.8
Current: -6
1.6
2183.8

More Statistics

Revenue (TTM) (Mil) $167.8
EPS (TTM) $ -0.53
Beta1.20
Short Percentage of Float15.01%
52-Week Range $4.14 - 7.74
Shares Outstanding (Mil)69.22

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 132 94 98
EPS ($) -0.90 -0.86 -0.09
EPS w/o NRI ($) -0.90 -0.86 -0.09
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
AT&T Will Benefit From DirecTV Acquistion Aug 14 2015 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
ETF’s with exposure to Spectrum Pharmaceuticals, Inc. : July 20, 2016 Jul 20 2016
Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation Jul 13 2016
Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation Jul 13 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 13 2016
ETF’s with exposure to Spectrum Pharmaceuticals, Inc. : July 6, 2016 Jul 06 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Cantor Fitzgerald's 2nd Annual... Jul 06 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Cantor Fitzgerald’s 2nd Annual... Jul 06 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 01 2016
Forget Valeant, Invest in These Attractive Drug Stocks Instead Jun 28 2016
ETF’s with exposure to Spectrum Pharmaceuticals, Inc. : June 21, 2016 Jun 21 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jun 09 2016
Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of... Jun 09 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on... Jun 01 2016
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on... Jun 01 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 31 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 25 2016
ETF’s with exposure to Spectrum Pharmaceuticals, Inc. : May 19, 2016 May 18 2016
Spectrum Pharmaceuticals, Inc. :SPPI-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
SPECTRUM PHARMACEUTICALS INC Financials May 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)